Stocksigma LogoStocksigma Logo

CARE Ratings Confirms Zero Deviation in Grasim Industries' ₹4,000 Crore Rights Issue Utilization

CARE Ratings' Monitoring Agency Report for the quarter ended 30th Sep'26 confirms zero deviation in Grasim Industries' utilization of its ₹3,999.80 crore

CARE Ratings Confirms Zero Deviation in Grasim Industries' ₹4,000 Crore Rights Issue Utilization

Grasim Industries Ltd · Others (Uncategorized) · 13 Nov 2026, 8:19 pm

CARE Ratings Confirms Zero Deviation in Grasim Industries' ₹4,000 Crore Rights Issue Utilization CARE Ratings' Monitoring Agency Report for the quarter ended 30th Sep'26 confirms zero deviation in Grasim Industries' utilization of its ₹3,999.80 crore rights issue proceeds. Out of ₹3,972.85 crore received, ₹3,971.81 crore has been deployed, including ₹3,000.00 crore fully utilized for debt repayment/prepayment and ₹971.81 crore for general corporate purposes (₹0.70 crore deployed in Q2FY27 for employee expenses). An unutilized balance of ₹0.90 crore remains in the monitoring account net of issue expenses. Post-issue promoter shareholding increased from 42.75% to 45.20%.

Original exchange filing (PDF)

More announcements from Grasim Industries Ltd

All Grasim Industries Ltd announcements